Table 1.

Effects of temozolomide and O6BG on DM6 melanoma xenografts

GroupQuintupling time, mean ± SE (d)Growth delay (d)No. regressions
No modulation
    ILI + 10% DMSO (control; n = 6)18.8 ± 2.21/6
    ILI + 350 mg/kg temozolomide (n = 6)17.3 ± 2.4−1.53/6
    ILI + 750 mg/kg temozolomide (n = 6)23.8 ± 4.35.13/6
    ILI + 750 mg/kg temozolomide (n = 6) with 40% PEG in PBS systemically × 5 d20.6 ± 3.13.32/6
Modulation with 3.5 mg/kg O6BG × 1 d
    ILI + 350 mg/kg temozolomide (n = 6)30.4 ± 4.811.73/6
    ILI + 750 mg/kg temozolomide (n = 6)42.5 ± 8.2*23.85/6
Modulation with 3.5 mg/kg O6BG × 5 d
    ILI + 10% DMSO (control; n = 6)17.3 ± 2.50/6
    ILI + 350 mg/kg temozolomide (n = 6)39.8 ± 4.5§22.65/6§
    ILI + 750 mg/kg temozolomide (n = 6)50.2 ± 5.5§32.96/6§
    Systemic 35 mg/kg temozolomide (n = 6)13.7 ± 3.2−3.50/6
  • Abbreviation: ILI, isolated limb infusion.

  • * P < 0.01, versus ILI + 10% DMSO.

  • P < 0.05, versus ILI + 10% DMSO.

  • ILI with temozolomide or 10% DMSO was done 2 hours after first O6BG i.p. administration. O6BG was given every 24 hours for the next 4 days.

  • § P < 0.01, versus ILI + 10% DMSO with 3.5 mg/kg O6BG for consecutive 5 days.